(16 references)-
- 抗原
- HLA-A2
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- PE
-
应用范围
- Flow Cytometry (FACS)
- 特异性
- The antibody BB7.2 recognizes an extracellular epitope at the C-terminus of alpha-2 helix and a turn on one of the underlying beta strands within the human HLA-A2 histocompatibility antigen.
- 交叉反应 （详细）
- Human
- 纯化方法
- Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
- 免疫原
- HLA-A2 solubilised by papain
- 克隆位点
- BB7-2
- 亚型
- IgG2b
-
anti-HLA-A2 antibody
适用: 人 FACS, IP 宿主: 小鼠 Monoclonal BB7-2 unconjugated
anti-HLA-A2 antibody适用: 人 FACS, IP, IHC (fro), IHC, Func, IHC (p) 宿主: 小鼠 Monoclonal BB7-2 unconjugated
anti-HLA-A2 antibody适用: 人 FACS, IP, IHC (fro) 宿主: 小鼠 Monoclonal BB7-2 unconjugated
anti-HLA-A2 antibody适用: 人 FACS, IP, IHC (fro), Func 宿主: 小鼠 Monoclonal BB7-2 unconjugated
-
- 应用备注
- Flow cytometry: The reagent is designed for analysis of human blood cells using 20 μL reagent / 100 μL of whole blood or 106 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
- 说明
-
The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
- 限制
- 仅限研究用
-
- 溶解方式
- No reconstitution is necessary.
- 缓冲液
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 注意事项
-
Do not freeze.
Avoid prolonged exposure to light. - 储存条件
- 4 °C
- 储存方法
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
: "A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China." in: Cellular & molecular immunology, Vol. 3, Issue 6, pp. 453-8, (2007) (PubMed).
: "Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells." in: Obstetrics and gynecology, Vol. 96, Issue 3, pp. 422-30, (2000) (PubMed).
: "Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient." in: Human immunology, Vol. 60, Issue 12, pp. 1195-206, (2000) (PubMed).
: "Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides." in: Human immunology, Vol. 59, Issue 7, pp. 443-50, (1999) (PubMed).
: "A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation." in: Human immunology, Vol. 49, Issue 1, pp. 28-37, (1997) (PubMed).
: "A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide." in: International immunology, Vol. 7, Issue 10, pp. 1599-605, (1996) (PubMed).
: "Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes." in: European journal of immunology, Vol. 23, Issue 6, pp. 1215-9, (1993) (PubMed).
: "Localization and characterization of serologic epitopes on HLA-A2." in: Human immunology, Vol. 33, Issue 3, pp. 185-92, (1992) (PubMed).
: "Selective changes in expression of HLA class I polymorphic determinants in human solid tumors." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 17, pp. 6719-23, (1989) (PubMed).
: "Molecular characterization of serologic recognition sites in the human HLA-A2 molecule." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 141, Issue 8, pp. 2811-8, (1988) (PubMed).
: "HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients." in: Human immunology, Vol. 18, Issue 4, pp. 277-85, (1987) (PubMed).
: "Clonal T lymphocyte recognition of the fine structure of the HLA-A2 molecule." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 135, Issue 1, pp. 384-90, (1985) (PubMed).
: "Structural analysis of HLA-A2 antigen from immunoselected mutant 8.6.1: further definition of an HLA-A2-specific serological determinant." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 131, Issue 6, pp. 2935-8, (1984) (PubMed).
: "HLA-A2 mutants immunoselected in vitro. Definition of residues contributing to an HLA-A2-specific serological determinant." in: The Journal of experimental medicine, Vol. 157, Issue 1, pp. 324-36, (1983) (PubMed).
: "HLA antigen structural gene mutants selected with an allospecific monoclonal antibody." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 79, Issue 24, pp. 7832-6, (1983) (PubMed).
: "Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28." in: Human immunology, Vol. 3, Issue 4, pp. 277-99, (1982) (PubMed).
-
: "A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China." in: Cellular & molecular immunology, Vol. 3, Issue 6, pp. 453-8, (2007) (PubMed).
-
- 抗原
- HLA-A2
- 物质类
- Influenza Protein
- 背景
- HLA-A2 (44 kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumour defence.
-
You are here:
